Publication of the cash position and revenues as of September 30, 2024
21st November 2024
Focus
Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology.
Our pipeline
Science
The panNASH initiative contributes to a better understanding of NASH and the specific importance of panPPAR agonism in the treatment of this disease.
Pannash WebsitePartnerships
Licensing and collaboration agreements in place with Sino Biopharm and Hepalys Pharma, Inc.
Hepalys Pharma, Inc.Inventiva in Numbers
2
Partnerships (Sino Biopharm and Hepalys Pharma, Inc.)
2
Innovative Clinical Programs
80
People in our Scientific Team
12
Patent Families
A Library of
240,000
Compounds
Welcome to Inventiva Pharma
We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.
We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.
By leveraging these assets and expertise, we are advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.
About InventivaFinancial Information
Latest Results
Upcoming Events
Publication of the cash position and revenues as of December 31, 2024
13th February 2025
Euronext Share Information
€2.51 -2.71%Last update: Nov 21, 2024 at 11:01 CET
Open: €2.58
Previous close: €2.58
Day High: €2.58
Day Low: €2.5
Therapeutic Areas
Non-Alcoholic Steatohepatitis (NASH)
Inventiva is developing lanifibranor for the treatment of NASH to address all the key features of this disease: accumulation of liver fat (steatosis), inflammation (hepatitis), injury of liver cells (ballooning), as well as scarring of the liver (fibrosis) that can ultimately lead to cirrhosis. The progression of fibrosis to cirrhosis, and its complications, is especially relevant in determining the outcome of the disease with regard to morbidity and survival.
Lanifibranor has completed a phase IIb study. After 6 months of treatment, lanifibranor showed statistically significant efficacy for the regulatory endpoints required by FDA and EMA: resolution of NASH* without worsening of fibrosis, reduction in fibrosis without worsening of NASH** and in the composite endpoint of patients achieving resolution of NASH with improvement in fibrosis. These efficacy results, together with a favorable safety profile, led to Breakthrough Therapy Designation by the FDA. For more details of the headline results see the results presentation.
Based on the positive results of the phase IIb study, Inventiva has initiated a pivotal phase III clinical trial, NATiV3, evaluating lanifibranor for the treatment of NASH.
[Clinicaltrials.gov NCT04849728].
* Resolution of NASH and no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline (NAS-Fibrosis)
** Improvement of liver fibrosis ≥ 1 stage and no worsening of NASH at week 24
Mucopolysaccharidosis (MPS)
MPS is a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells.
Inventiva is developing odiparcil, an orally-available small molecule designed to modify how GAGs are synthesized.
In the recently completed iMProveS phase IIa study, odiparcil confirmed its favourable safety profile and demonstrated efficacy in adult MPS VI patients, especially in tissues types not reached by standard of care.
